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Introduction: Osteoporotic hip fractures present a
significant global challenge to patients, clinicians and
healthcare systems. It is estimated that hip fracture
accounts for 1.4% of total social and healthcare costs
in the established market economies.
Methods and analysis: The World Hip Trauma
Evaluation (WHiTE) was set up to measure outcome in
a comprehensive cohort of UK patients with hip
fracture. All patients in the cohort are treated under a
single comprehensive treatment pathway. A core
outcome set, including health-related quality of life, is
collected on all the patients. This protocol describes
the current multicentre project that will be used as a
vehicle to deliver a series of embedded observational
studies.
Ethics and dissemination: Research Ethics
Committee approval was granted (Rec reference 11/LO/
0927, approved 18/8/2011) and each hospital trust
provided National Health Service (NHS) approvals.
Trial registration number: The study is registered
with National Institute of Health Research Portfolio
(UKCRN ID 12351) and the ISRCTN registry
(ISRCTN63982700).
INTRODUCTION
The World Hip Trauma Evaluation (WHiTE)
project was set up to measure outcome in a
comprehensive cohort of UK patients with
hip fracture. All patients in the cohort are
treated under a single comprehensive treat-
ment pathway. A core outcome set, including
health-related quality of life (QoL), is col-
lected on all the patients.
This protocol describes the current multi-
centre project that will be used as a vehicle
to deliver a series of embedded observational
studies.
Osteoporotic hip fractures present a signiﬁ-
cant global challenge to patients, clinicians
and healthcare systems. It is estimated that
hip fracture accounts for 1.4% of total social
and healthcare costs in the established
market economies.1 Approximately 8.5% of
patients with hip fracture will die within
30 days of injury2 and 22.5% within 12
months.2 3 In addition, the majority of survi-
vors experience a signiﬁcant reduction in
health-related QoL.4 5 The challenge is
expected to intensify with a rise from the 1.3
million hip fractures in 1990 to 6.3 million
globally by 2050.6
The National Hip Fracture Database
(NHFD) already captures data on almost all
patients with hip fracture in England, Wales
and Northern Ireland.7 Although it is used
principally for national clinical audit, there is
considerable potential to use the NHFD for
research purposes.3 However, the NHFD
does not routinely capture patient-reported
outcome measures and there is substantial
variation in clinical decision-making (eg,
choice of ﬁxation device) between hospitals
and individual surgeons, which risks introdu-
cing confounding to observational studies
embedded within the NHFD.8
In order to address these limitations, we
established the Warwick Hip Trauma
Evaluation (WHiTE) study to measure
outcome in a comprehensive cohort of hip
fracture patients within the framework of the
NHFD.9–13 This study was renamed ‘World
Hip Trauma Evaluation’ following the deci-
sion to make the project multicentre in 2015.
The WHiTE project is nested within the
NHFD and all patients are treated under a
single comprehensive treatment pathway that
is based on the National Institute for Health
and Care Excellence (NICE) Hip Fracture
Guidelines.14 This should help limit unex-
plained variability in clinical decision-
making. The WHiTE project will also enrich
the NHFD data by collecting patient-
reported outcome measures and functional
status after discharge from hospital. These
are included within a ‘core outcome set’ that
has been established for this patient group;
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both outcome measures and data collection systems
were tested in a series of single-centre pilot investiga-
tions.11–13
As WHiTE is nested within a clinical registry, it will
capture variables (eg, fracture pattern and operation
type) that are particularly important for hip fracture
research. The data are also collected prospectively by
dedicated research associates at each hospital site for the
principle purpose of research. It will therefore provide a
richer resource for hip fracture research than existing
UK administrative data sets, such as Hospital Episode
Statistics (HES) and the Clinical Practice Research
Datalink (CPRD).
Objective
The objective of the WHiTE project is to provide a data
collection framework in which a series of observational
studies can be embedded by hip fracture researchers.
PATIENTS AND METHODS
Eligibility
All patients presenting with a hip fracture to one of the
recruiting National Health Service (NHS) sites and who
would currently be reported to the NHFD. Alignment
with the NHFD eligibility criteria will reduce the data
collection burden at recruiting sites, which is important
for its sustainability as further studies are embedded
within the WHiTE framework. The NHFD exclusion cri-
teria are:
▸ Age <60 years.
▸ Non-operative treatment.7
Throughout the study, screening logs will be kept to
determine the number of patients assessed for eligibility
and reasons for any exclusion. Patients who decline to
consent to take part will be given the opportunity to
inform the research team of the reasoning behind their
decision not to participate.
Consent
Patients with a hip fracture are a clinical priority for
urgent operative care and will usually undergo surgery
on the next available trauma operating list. All WHiTE
recruiting sites treat hip fracture patients according to
national guidelines and so patients will be managed
according to a series of common standard treatment
pathways. The WHiTE study will not affect their treat-
ment in any way. The patients will be approached for
consent to be part of this cohort study in the immediate
postoperative period.
At the ﬁrst appropriate time when the patient has
regained capacity (usually the ﬁrst day after surgery) a
research associate will provide the participant with the
study information. The patient will be given the oppor-
tunity to ask questions and discuss the study with their
family and carers for as long as they require. They will
then be asked to provide written consent to participate in
the study. If the patient does not wish to complete
questionnaires for the study at this stage, they will be
asked if they are happy to provide written consent for us
to access and use any routine NHS data, including that
collected through the NHFD. Alternatively the patient
can choose to decline to have any data entered into the
study.
Best efforts will be made to involve participants who,
temporarily or permanently, lack capacity in the decision
to be involved in the study. The clinical team will make a
judgement about the amount and complexity of the
information that the participant is able to understand
and retain on an individual basis. Appropriate informa-
tion will be communicated to the participant and
updated as their understanding changes. In the event
that a patient has temporary loss of capacity, we will
follow best practice and ask the patient for consent as
soon as they are able to do so.
In accordance with section 32 subsection 9b of the
Mental Capacity Act 2005, where a patient does not have
capacity to consent for themselves, we will seek agree-
ment from an appropriate consultee.
Where a personal consultee is available, they will be
provided with the study information. The personal con-
sultee will be given the opportunity to ask questions and
discuss the study after which they will be asked to
provide agreement, which will be documented. The per-
sonal consultee will complete the outcome question-
naires on behalf of the patient.
Where a personal consultee is not available, a nomi-
nated consultee will be identiﬁed to advise the research
team. This person will be the patient’s treating surgeon
and/or their treating general practitioner. If their
surgeon is a member of the research team, another
independent surgeon will be identiﬁed.
If the patient withdraws from the study, data collected
up until the point of withdrawal will be included in any
subsequent analyses.
At all times the chief investigator will act in accordance
with the patients’ best interests. Any new information that
arises during the trial that may affect participants’ willing-
ness to take part will be reviewed by the Oversight
Committee; if necessary this will be communicated to all
participants and a revised consent form completed.
Standardised treatment pathway
Participants will be treated in accordance with a standar-
dised care pathway from diagnosis to ﬁnal discharge
from hospital. This pathway is described below and is in
accordance with national guidance issued by NICE.14
Preoperative assessments: Participants will usually be
assessed in the emergency department. Diagnosis of a
fracture of the hip will be conﬁrmed by appropriate
radiographic images. Where there is doubt over the
presence or the radiological pattern of the fracture,
further imaging will be performed as per routine clinical
practice.
All participants will have initial assessment as part of a
multidisciplinary pathway and will undergo the following
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investigations as a minimum: ECG, full blood count,
group and save, and tests of renal function. A cognitive
assessment will be undertaken.
Routine thromboprophylaxis will be started in all par-
ticipants not already receiving anticoagulant therapy.
Chemical and mechanical prophylaxis measures will be
used in accordance with current protocols agreed at
each centre.
Anaesthetic technique: A regional or general anaesthesia
technique will be used for every participant. The anaes-
thetic procedure may incorporate a local anaesthetic
nerve block using either a nerve stimulator or
ultrasound-guided technique or periarticular analgesic
injections in accordance with local protocols.
Fracture pattern: Fracture patterns will be classiﬁed pre-
operatively from the radiographs into four groups:
▸ Group 1: undisplaced/valgus impacted intracapsular;
▸ Group 2: displaced intracapsular;
▸ Group 3: trochanteric—fractures centred within the
trochanteric region;
▸ Group 4: subtrochanteric—fractures centred within
the region 5 cm below the lesser trochanter.
Operative intervention: All participants should aim to
have surgery on the day or the day after injury on a
consultant-led operating list. All participants will receive
perioperative prophylactic antibiotics in accordance with
current protocols agreed at each centre.
▸ Group 1: undisplaced intracapsular fractures: all partici-
pants will have their fracture ﬁxed in situ. Internal
ﬁxation of the fracture will be achieved through a
standard mini open lateral or percutaneous approach
with parallel cannulated screws.
▸ Group 2: displaced intracapsular fractures: the operating
surgeon will perform their preferred approach. The
hip will be dislocated and the head excised. There
are two subgroups:
– The majority of patients with low prefracture func-
tional demand—a proven hemiarthroplasty femoral
component will be cemented into the femur using
a third generation cementing technique.
– A subgroup of patients with high prefracture func-
tional demand—total hip replacement (THR),
where the acetabulum is also replaced. Given the
lack of evidence to support criteria to select those
participants who might beneﬁt from THR a prag-
matic approach will be adopted. Eligibility for this
subgroup will be determined by the treating ortho-
paedic surgeon, on the basis that he or she believes
the participant would beneﬁt from total hip arthro-
plasty. In the event of a participant undergoing
THR the approach, implant and operative tech-
nique employed would be at the discretion of the
operating surgeon.
▸ Group 3: trochanteric fractures: All participants will
undergo reduction of their fracture on a fracture
table. There are three subgroups:
– Stable standard-obliquity fractures (AO/OTA A1)—
internal ﬁxation with a sliding hip screw.
– Unstable standard-obliquity fractures (AO/OTA A2)
—internal ﬁxation using a sliding hip screw.
– Unstable reverse obliquity or fractures at the level
of the lesser trochanter (AO/OTA A3)—internal
ﬁxation with a distally locked, cephalomedullary
device.
▸ Group 4: subtrochanteric fractures: All participants will
undergo reduction of their fracture on a fracture
table. Internal ﬁxation of the fracture will be achieved
using a distally locked, cephalomedullary device.
Postoperative rehabilitation: Post-operative analgesia will
be prescribed perioperatively and reviewed by the
responsible clinical teams as appropriate. In the post-
operative period, participants will undergo an initial
physiotherapy and occupational therapy trauma assess-
ment. A full social, cognitive, premorbid function and
falls history will be obtained and documented. An initial
rehabilitation plan will be followed with all participants.
All patients will undergo both a bone health assessment
and falls risk assessment as per usual care.
Discharge from hospital: Participants will be discharged
from the acute orthopaedic trauma ward at the earliest
safe opportunity to the most appropriate discharge des-
tination as determined by the multidisciplinary team.
Outcome data
In this study, we will use techniques common in long-
term cohort studies to ensure minimum loss to
follow-up.
We will attempt to contact the patient or next of kin
by telephone. If this fails we will send the patient or next
of kin a postal questionnaire to complete with a prepaid
return envelope. Finally the general practitioners of
those participants who are deemed ‘lost to follow-up’
will be contacted in order to attempt to complete the
follow-up. If all these methods fail, then we will class the
patient as a non-responder for that time point.
Health-related QoL score (EQ-5D): EuroQol (EQ-5D-5L)
at 4 months postinjury, adjusted for preinjury score. The
EQ-5D-5L is a validated self-administered patient-
reported outcome measure and requires 5 min to com-
plete. EQ-5D is a generic health-related QoL measure
consisting of ﬁve dimensions each with a ﬁve-level
answer possibility. Each combination of answers pro-
duces a health proﬁle which can be converted into an
estimated health utility score after applying a set of pref-
erence weights.15 The preliminary English social value
set obtained from general population preferences will
be used16 to estimate health utilities until one for the
UK is produced and made available. The EQ-5D has
good test–retest reliability, is simple for patients to use,
and gives a single preference-based index value for
health status that can be used for broader cost-
effectiveness comparative purposes.
Residential status: Prefracture and current residential
status will be collected at 4 months. The possible
responses for residential status are: own home/sheltered
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housing, residential care, nursing home, rehabilitation
unit, acute hospital, dead, other.
Mobility status: Prefracture and current mobility status
will be collected at 4 months. The possible responses for
mobility status are: freely mobile without aids, mobile
outdoors with one aid, mobile outdoors with two aids or
frame, some indoor mobility but never goes outside
without help, no functional mobility (using lower
limbs).
Hospital information: Admission including admission
dates and orthopaedic/orthogeriatrician details. Assessment
including Abbreviated Mental Test Score, pathological
fracture and preoperative medical assessment information
along with fracture classiﬁcation and side. Treatment
including operation details. Discharge including dis-
charge summary.
Complications: The complications that we will report as
‘expected’ following hip fracture are: wound infection,
respiratory infection, urinary tract infection, venous
thromboembolism, cerebrovascular accident, cardiac
event, failure of ﬁxation, dislocation, blood transfusion.
End of study
All patients will be followed up to collect data on their
status at 4 months postoperation. If contact cannot be
made or data collected within 3 months of this point,
follow-up will not be collected. After the 4-month
follow-up, participants will be treated as per normal
standard of care with no further study-speciﬁc follow-up.
Data collection and data management
Personal data collected during the trial will be handled
and stored in accordance with the 1998 Data Protection
Act and CTU Standard Operating Procedures.
The data collected from participants will be entered in
the study and NHFD databases. All data collected will be
anonymised after the collection of the baseline demo-
graphic data and all participants given a unique study
number. Identiﬁable participant data will be held on a
separate database and in a locked ﬁling cabinet and
coded with a study participant number to tag identiﬁ-
able data to the outcome data.
With the patient’s consent, data may be linked to
routine NHS and social care data sets via the Health and
Social Care Information Centre or appropriate body.
Disclosure of conﬁdential information will only be
given if a participant indicates an issue that may jeopard-
ise the safety of the participant or another person.
Oversight Committee
The Oversight Committee comprises of representatives
from each of the professional groups involved in the
care of patients with hip fracture and lay representatives
of the patient group. They will collectively manage the
data governance arrangements, although ﬁnal responsi-
bility will lie with the chief investigator.
DATA ANALYSIS
Observational studies
The WHiTE framework will be suitable for addressing a
broad range of hip fracture research questions, either
alone or in concert with national data from its parent
registry, the NHFD. It will not be suitable for studies
relating to younger adults with hip fractures or those
treated non-operatively. An illustrative list of the types of
research question for which WHiTE may be suitable
includes:
Descriptive epidemiology: Describing the occurrence and
distribution of hip fractures in the UK, for example, is
there an association between socioeconomic status and
outcome, including loss of health-related QoL, after hip
fracture?
Health services research: Exploring the effects of differ-
ences in healthcare delivery, for example, does hospital
hip fracture volume affect patient outcomes?
Outcome studies: Studying the impact of treatment deci-
sions on patients, for example, does compliance with
NICE guidelines improve outcomes for patients with hip
fractures?
The Oversight Committee will prioritise individual
study ideas and manage the application process for
using WHiTE data. They will prospectively approve study
applications in advance of any data being shared or
analysed.
Sample size
A sample size for a study such as the one we propose
here is difﬁcult to determine with any degree of preci-
sion. This is, in large part, due to the ﬂexibility of the
approach being adopted, that is, speciﬁc research ques-
tions will be identiﬁed by the Oversight Committee over
time.
However, there are aspects that are determined a
priori that can guide an initial sample size. A key deter-
minant of the sample size, and also an important
outcome in itself, in this frail (elderly) population is the
death rate. Previous analyses5 13 have shown that the
death rate in this group is between 20% and 30% at
12 months, but data were sparse and limited. One
research question that we know will be important is to
establish the overall population death rate and model
how it changes in the immediate postoperative period.
Table 1 shows 95% CIs for estimates of death rates of




100 (12.9 to 29.4) (21.5 to 40.1)
300 (15.7 to 25.1) (24.9 to 35.6)
1000 (17.6 to 22.6) (27.2 to 33.0)
3000 (18.6 to 21.5) (28.4 to 31.7)
6000 (19.0 to 21.0) (28.8 to 31.2)








pen: first published as 10.1136/bmjopen-2016-011679 on 21 October 2016. Downloaded from 
20% and 30% for varying sample sizes (n), based on a
binomial model.
In order to estimate the death rate to a high level of
precision (within 1%), a reasonable target overall
sample size is therefore ∼6000 participants. The death
rate is likely to vary within important subgroups of the
population (eg, fracture type), so it is also important to
consider the precision of estimation of the death rate
within the smallest clinically important subgroup, which
we think is likely to be in the order of 5% of the overall
population. Based on 6000 participants, this amounts to
a subgroup of 300, and a CI of ∼10% for estimating the
death rate.
Formal analyses will be undertaken, after identiﬁcation
of important research questions by the Oversight
Committee, using multiple regression analyses with QoL
(EQ-5D) as the response variable. Therefore, Cohen’s f2
provides a useful way for characterising the probable
effect size when ﬁtting such models for continuous out-
comes.17 Sticking with the above setting, and the smal-
lest clinically important subgroup (n=300) indicates that
we will have 95% and 75% power to detect an effect size
of 0.08 and 0.05, respectively, at the 5% level in this
population and assuming we use 10 degrees of freedom
for model ﬁtting. Typical values of f2 of 0.02 and 0.15
represent small and moderate effects sizes, so values in
the range 0.05–0.08 are small to moderate. Cohen’s f2 is
determined by the ratio of the proportion of variance
accounted for in the multiple regression model (regres-
sion R2 value) to one minus that proportion. Experience
suggests that R2 values are often small (10–20%) in the
setting described here, as QoL is very variable and much
of the variability will not be captured by the small
number of explanatory variables we will have available
for model ﬁtting. Nevertheless, even if models account
for only 10% of the variance in QoL we should still have
considerable power (>80%) to address important regres-
sion relationships within our subgroups of size 300, even
allowing some reduction in this number for loss to
follow-up.
In summary, an initial sample size of 6000 patients will
provide considerable power to estimate overall popula-
tion characteristics such as death with a high level of
precision. Assuming that we are interested in clinically
signiﬁcant subgroups no smaller than 5% of this total
(n=300) we will have good power to detect small to mod-
erate effects sizes in our planned multiple regression
analyses. On average, each of the WHiTE recruitment
sites treats 500 patients with hip fracture a year (range
300–700; NHFD reports) and so we anticipate reaching
the 6000 patient sample in 2017.
It is anticipated that the data generated by the cohort
study will be used to support and inform hypotheses that
are suggested by clinical practice. The Oversight
Committee will decide whether any interim analyses are
necessary to inform future questions in order to prevent
repeated attempts to interrogate the data set without a
priori hypotheses. The cohort study data will also be
used to update estimates of ‘nuisance’ parameters, such
as the death rate and QoL variability in the study popu-
lation. These nuisance parameters will be used to reﬁne
estimates of sample sizes for future embedded rando-
mised controlled trials.
An example observational study within the WHiTE
observational cohort might investigate whether the type
of fracture a patient sustains inﬂuences the patient’s
outcome. While the optimal interventions for each frac-
ture pattern are deﬁned in current guidelines, the effect
of fracture pattern on patient outcome is not well under-
stood. Data from the NHFD 2014 report (n=64 838) give
a breakdown of fracture types as follows: undisplaced
intracapsular 9.5% (n=6165), displaced intracapsular
48.8% (n=31 656), trochanteric 34.6% (n=22 422), sub-
trochanteric 5.4% (n=3507) and not speciﬁed 1.7%
(n=1088). Suppose we were interested in understanding
the relationship between the type of intervention, anae-
thestic and rehabilitation within the subtrochanteric
fracture subgroup. This subgroup comprises ∼5.4%
(n=325) of the study population (n=6000). Let us
assume 90% follow-up rates at 4 months (ie, n is ∼300),
with EQ-5D as the primary outcome, and the deﬁnitive
analysis is a multiple linear regression adjusting for age
and gender as minimum. Taking a conservative estimate
of R25 13 to give a value of Cohen’s f2 of 0.05, suggests
that we will have 85% power to detect a statistically sig-
niﬁcant regression analysis, at the 5% level, in the smal-
lest subgroup of interest (subtrochanteric fractures) for
a sample size of 300 patients. A 4-month follow-up rate
of >90% is anticipated based on a WHiTE pilot study,
which successfully followed up 88% of patients at
12 months.5
Analogous economic burden and health economic
assessments will be integrated into the analysis plan for
each observational study. The economic assessments will
be conducted from the recommended NHS and per-
sonal social services perspective.
Validation
Once the initial sample size of 6000 patients has been
achieved, we will use other data sets to externally validate
the cohort and determine its generalisability. In particu-
lar, we will explore the NHFD, HES and the CPRD to
determine whether the WHiTE cohort is truly represen-
tative (eg, in terms of age structure) of the wider UK
hip fracture population. This should help contextualise
WHiTE data before they are used to determine research
priorities and inform health policy.
Dissemination and publication
The results of this study will be disseminated to the hip
fracture clinical community via presentations at national
and international meetings as well as publication in
peer-reviewed journals and social media. Patient reports
will also be made available to participants and the wider
public via newsletters and podcasts. The results of the
observational studies will inﬂuence the next generation
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of hip fracture guidelines, for example the UK NICE
Hip Fracture Guidelines, and generate hypotheses that
can be tested in interventional study designs.
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